Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age14-18
SponsorUniversity of Michigan
About this trial
This research study collects health-related information and blood samples to better understand how body composition, lifestyle habits, and diet influence meta-inflammatory monocytes (MiMos) in adolescents. The hypothesis of this study is that adolescents at risk for metabolic disease have enhanced MiMo related activities leading to insulin resistance.
Eligibility criteria
Qualifiers
Between 14 and 18 years of age
Tanner stage 4 or 5 (mature adult stage of puberty)
Normal weight (BMI ≥ 5th percentile & < 85th percentile), overweight (BMI > 86th percentile) & < 94th percentile), obese weight (BMI percentile ≥ 95th percentile), and/or pre-diabetes (HbA1c > 5.7%)
For Type 2 Diabetes cohort, diagnosis of Type 2 Diabetes
Disqualifiers
Currently pregnant
Use medications known to affect glucose metabolism (immunosuppressive medications, cancer medications, or high dose steroids), unless prescribed for Type 2 Diabetes management
Prior diagnosis of autoimmune disease, cancer, or a cognitive or perceptual disability that would inhibit following directions of study staff
Allergies or intolerance to milk, soy, or palm oil
Trial design
Treatments tested in this trial
- Not listed
Trial groups
175 Participants
are grouped into 5 trial groupsSponsors and collaborators
University of Michigan
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Source ClinicalTrials.gov